Page 96 - ம்ட் ஆண்டர்சன் புற்றுநோய் மையம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Clinical data quashes experimental Covid-19 therapies from Brii, Vir & Apellis Antibody therapies from Brii Biosciences and Vir Biotechnology failed to show sufficient efficacy to advance to the next stage of an NIH-sponsored Covid-19 clinical trial. Apellis Pharmaceuticals and Durect also stopped work on experimental Covid treatments. Shares0   Drug developers are still trying different approaches to treating Covid-19 but clinical trial results this week halted several potential therapies, including two that are part of a National Institutes of Health program evaluating treatments for hospitalized patients. The NIH’s Accelerating Covid-19 Therapeutic Interventions and Vaccines (ACTIV) program launched to speed up the development and testing of treatments and vaccines. The study uses an adaptive two-stage design for the Phase 3 test. A treatment that demonstrates safety in stage 1 can proceed to stage 2, following review by an independent board.

North carolinaUnited statesSouth africaZhi hongBrii biosciencesApellis covidGilead sciencesVanderbilt university medical centerApellis pharmaceuticalsNational institutes of healthNational institutesVir biotechnologyFrancisco based virWeight lossMedical devicesHealthcare innovation